This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

NY Family Wins $9 Billion In Trial Over Cancer Linked To Diabetes Drug Actos

LAFAYETTE, La., April 8, 2014 /PRNewswire/ -- A Louisiana jury has awarded $9 billion to a New York man and his wife following a trial over the man's claims that his bladder cancer was caused by the popular prescription diabetes drug Actos.

Attorneys W. Mark Lanier of The Lanier Law Firm, Richard J. Arsenault of Neblett Beard & Arsenault and Paul J. Pennock of Weitz & Luxenberg represented Terrence and Susan Allen in the two-month trial before Judge Rebecca Doherty in the U.S. District Court for the Western District of Louisiana.

In the April 7 verdict, jurors assessed punitive damages totaling $6 billion against Actos manufacturer Takeda Pharmaceutical Co. Ltd. of Osaka, Japan, and $3 billion against Indianapolis-based Eli Lilly & Co. (NYSE:LLY), which marketed the drug in the U.S. from its debut in 1999 to 2006. Actos generated more than $16 billion in sales since its release.

Trial evidence showed that experts warned of Actos' link to bladder cancer a full seven years before Takeda issued related warnings to patients. Mr. Allen began taking the medication in 2006 and was diagnosed with bladder cancer in 2011.

"Eight people from Lafayette, Louisiana, spoke loudly about how business is to be conducted in America," says Mr. Lanier. "This should be a wake-up call to any business that acts with reckless disregard for the safety of people."

Mr. Lanier and the other attorneys who won the $9 billion verdict on behalf of the Allen family also represent clients in many of the additional Actos cases that are currently pending. More than 2,700 Actos lawsuits have been consolidated in Judge Doherty's federal court, and Takeda and Eli Lilly face hundreds of state court claims throughout the U.S.

With offices in Houston, Los Angeles, and New York, The Lanier Law Firm is committed to addressing client concerns with effective and innovative solutions in courtrooms across the country. The firm is composed of outstanding trial attorneys with decades of experience handling cases involving pharmaceutical liability, personal injury, asbestos exposure, business litigation, product liability, maritime law, and sports and entertainment law.

For more information on the Actos verdict or to speak with Mr. Lanier, please contact J.D. Cargill at 713-659-5200.



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs